Search Results

PharmaNest Inc. announces today that it will present, alongside its collaborators, seven abstracts at this year’s International Liver Congress - EASL in Milan, Italy, June 5-8, 2024.

Alimentiv Inc., AcelaBio Inc., and PharmaNest Inc. are pleased to announce their collaborative effort aimed at revolutionizing precision medicine and artificial intelligence -enabled digital pathology solutions for metabolic dysfunction-associated steatohepatitis, previously known as nonalcoholic steatohepatitis clinical trials.

PharmaNest, an emerging leader in quantitative Digital Pathology and Artificial Intelligence, announces today that it will be present, alongside with its collaborators, eight presentations at this year’s International Liver Congress (ILC) in London, June 22-25, 2022.

PharmaNest is an image analysis company focused in the development and validation of novel standards for the quantification of Fibrosis and associated histological features for drug discovery and development. Recently, PharmaNest announced the launch of its FibroNest cloud-based and multi-vendor platform for the automated quantification of Fibrosis for non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH)

Acerus Pharmaceuticals Corporation today announced that it has entered into an exclusive agreement to commercialize Pharmanest AB (“Pharmanest”) Short Acting Lidocaine product (“SHACT”), a novel pain relief drug device combination in Canada.

Karolinska Development AB today announces that the company will receive 140,149 shares in Pharmanest AB. Furthermore, the company will receive 11,527 shares via KCIF Co-Investment Fund.

FibroNest cloud-based image analysis tool provides the most advanced phenotypic image analysis and translational platform for the automated quantification of fibrosis and steatosis for NASH and for other fibrotic conditions in drug discovery and drug development projects.

Karolinska Development’s portfolio company Phamanest changes its name to Palette Life Sciences. The company also announces a global licensing agreement with Nestlé Skin Health.

Sagimet Biosciences Inc. will present preclinical data at the 7th Obesity and NASH Drug Development Summit on November 28, 2023, in Boston.